Literature DB >> 26202506

Clinical significance of increased expression of Nijmegen breakage syndrome gene (NBS1) in human primary liver cancer.

Yan Wang1, Man Li2, Jiang Long3, Xiao-Yan Shi4, Qian Li5, Jia Chen5, Wei-Min Tong2, Ji-Dong Jia6, Jian Huang7.   

Abstract

PURPOSE: As a DNA repair-associated gene essential for maintaining genomic instability, Nijmegen breakage syndrome gene (NBS1), codes for a protein, Nbs1(p95/Nibrin), involved in the processing/repair of DNA double-strand breaks. The aim of this study is to investigate the molecular alteration of Nbs1 in human primary liver cancer, including HBV-associated hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
METHODS: The expression levels of Nbs1 in 110 cases of primary liver cancer, including 85 HCCs and 25 ICCs, were detected by immunohistochemistry, real-time RT-PCR and Western blot analysis. The percentage of Ki-67 antigen-positive cells and the level of phosphorylated histone H2AX (γ-H2AX) were detected to evaluate the relationship of Nbs1 expression with proliferation and the degree of DNA damage in HCC cells.
RESULTS: Increased Nbs1 expression was observed in tumor compared to corresponding adjacent non-tumor tissue in 54.6 and 47.3 % of HCC cases detected with frozen tissues and paraffin sections. Higher frequency of increased Nbs1 expression was shown in poorly differentiated HCCs (p = 0.0265) and in all poorly differentiated ICCs, indicating the increased Nbs1 expression is associated with the degree of malignancy of HCC cells. Moreover, the percentage of Ki-67-positive cells and the level of γ-H2AX correlate well with increased Nbs1 expression in HCC cases, suggesting an activated DNA damage response in proliferating HCC cells with increased Nbs1 expression.
CONCLUSION: Increased Nbs1 expression might play a significant role in liver cancer progression, and the status of Nbs1 expression might be helpful for evaluation of the degree of malignancy of primary liver cancer.

Entities:  

Keywords:  DNA repair; Double-strand breaks; Hepatocellular carcinoma; Nbs1 expression; Proliferation

Year:  2014        PMID: 26202506     DOI: 10.1007/s12072-013-9500-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  35 in total

1.  Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations.

Authors:  R Varon; E Seemanova; K Chrzanowska; O Hnateyko; D Piekutowska-Abramczuk; M Krajewska-Walasek; J Sykut-Cegielska; K Sperling; A Reis
Journal:  Eur J Hum Genet       Date:  2000-11       Impact factor: 4.246

2.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

Review 3.  Dual role of Nbs1 in the ataxia telangiectasia mutated-dependent DNA damage response.

Authors:  Joo-Hyeon Lee; Dae-Sik Lim
Journal:  FEBS J       Date:  2006-04       Impact factor: 5.542

Review 4.  The MRE11 complex: starting from the ends.

Authors:  Travis H Stracker; John H J Petrini
Journal:  Nat Rev Mol Cell Biol       Date:  2011-02       Impact factor: 94.444

5.  Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development.

Authors:  M Wilda; I Demuth; P Concannon; K Sperling; H Hameister
Journal:  Hum Mol Genet       Date:  2000-07-22       Impact factor: 6.150

6.  Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage.

Authors:  Xuan Huang; Zbigniew Darzynkiewicz
Journal:  Methods Mol Biol       Date:  2006

7.  Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt.

Authors:  Yen-Chung Chen; Yi-Ning Su; Po-Chien Chou; Wei-Chung Chiang; Ming-Cheng Chang; Liang-Shun Wang; Shu-Chun Teng; Kou-Juey Wu
Journal:  J Biol Chem       Date:  2005-07-21       Impact factor: 5.157

8.  Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours.

Authors:  Jerzy Nowak; Maria Mosor; Iwona Ziółkowska; Malgorzta Wierzbicka; Monika Pernak-Schwarz; Marta Przyborska; Krzysztof Roznowski; Andrzej Pławski; Ryszard Słomski; Danuta Januszkiewicz
Journal:  Eur J Cancer       Date:  2008-02-15       Impact factor: 9.162

Review 9.  Pathogenesis of hepatocellular carcinoma and molecular therapies.

Authors:  Beatriz Mínguez; Victoria Tovar; Derek Chiang; Augusto Villanueva; Josep M Llovet
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

10.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

View more
  3 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.

Authors:  Yu Hong; Jiang Long; Hai Li; Shuhong Chen; Qiqi Liu; Bei Zhang; Xiaomin He; Yan Wang; Hongyi Li; Yimei Li; Tao Zhang; Chenzhen Lu; Hao Yan; Minli Zhang; Qing Li; Bangwei Cao; Zhigang Bai; Jin Wang; Zhongtao Zhang; Shengtao Zhu; Jiasheng Zheng; Xiaojuan Ou; Hong Ma; Jidong Jia; Hong You; Shengqi Wang; Jian Huang
Journal:  EBioMedicine       Date:  2015-03-13       Impact factor: 8.143

3.  A non-synonymous polymorphism in NBS1 is associated with progression from chronic hepatitis B virus infection to hepatocellular carcinoma in a Chinese population.

Authors:  Ya'nan Zhen; Ruixue Xiao; Xing Chen; Changjin Yuan; Yanlai Sun; Jie Li
Journal:  Onco Targets Ther       Date:  2018-01-26       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.